Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2531-2540 Newer>

Pharmaceutical Executive November 1, 2005 Peter H. Nalen	Alternative Media: Targeting Audiences on the Web The most important web page to communicate with doctors and patients is the page of results that your potential customers see when they use search engines, such as Google, Yahoo!, or MSN.
Pharmaceutical Executive November 1, 2005 Peter Pitts	Opinion: It's All Relative PhRMA's new voluntary guidelines are about much more than direct-to-consumer advertising - and they're not really voluntary.
Pharmaceutical Executive November 1, 2005 Tamsen Valoir	Legal: State Compulsory Licenses The Supreme Court extended the power of eminent domain. Now states want to issue compulsory licenses under the same principle to control drug prices.
Pharmaceutical Executive November 1, 2005 Jill Wechsler	Washington Report: Out of Commission? Crawford Steps Down The clouded circumstances of the commissioner of the Food and Drug Administration may complicate the process of securing a permanent leader. Meanwhile, battles continue over hot-button issues such as the morning-after pill and the regulation of follow-on biologics.
Pharmaceutical Executive November 1, 2005 Patrick Clinton	From the Editor: Lost World Leo Sternbach was an extraordinary individual, whose death feels like the end of an era in pharmaceuticals.
Pharmaceutical Executive November 1, 2005 Sarah Houlton	Global Report: Drug Evaluation in the UK The availability of new medicines has been thrown into the limelight once more, with UK's National Institute for Health and Clinical Excellence being called upon to make dramatic improvements to the speed at which it carries out evaluations.
Pharmaceutical Executive November 1, 2005	Thought Leader: A Q&A with Steve Rauschkolb With new guidelines pressuring companies to demonstrate superior value, and an environment that will tolerate little else, pharma firms are looking toward innovation and technology to create better training methods.
Bio-IT World November 2005 Mark D. Uehling	The Unstoppable Swiss At a time when other pharmaceutical giants struggle to justify pediatric uses of their medicines, or to defend themselves against thousands of lawsuits, Novartis has one of the safest and strongest pipelines in the industry.
Bio-IT World November 2005 Patrick R. Scanlon	Patent Term Extension Primer U.S. patent law includes provisions for extending the patent term of medical devices and pharmaceuticals in instances when lengthy FDA approval is taking place during the term.
Bio-IT World November 2005 Khaleeli & Fernandez	Patent Prosecution and Enforcement in Pharmacogenomics Patenting the composition of an isolated nucleic acid sequence, an isolated protein, and small molecules is possible, but there are challenges claiming that they resulted from pharmacogenomic research.
<Older 2531-2540 Newer> Return to current articles.